Epitope Mapping of an Anti-Mouse CD39 Monoclonal Antibody using PA Scanning and RIEDL Scanning DOI Open Access
Hiroyuki Suzuki, Yuki Okada, Tomohiro Tanaka

et al.

Published: Dec. 6, 2023

A cell-surface ectonucleotidase CD39 mediates the conversion of extracellular ATP into immunosuppressive adenosine with another CD73. The elevated in tumor microenvironment (TME) attenuates antitumor immunity, which promotes cell immunologic escape and progression. Anti-CD39 monoclonal antibodies (mAbs), suppress enzymatic activity, can be applied to therapy. Therefore, an understanding relationship between inhibitory activity epitope mAbs is important. We previously established anti-mouse (mCD39) mAb, C39Mab-1 using Cell-Based Immunization Screening (CBIS) method. In this study, we determined critical flow cytometry. performed PA tag (12 amino acids)-substituted analysis (named scanning) RIEDL (5 determine By combination scanning scanning, identified conformational epitope, spanning three segments 275th 279th, 282nd 291st, 306th 323rd acids mCD39. These analyses would contribute identification membrane proteins.

Language: Английский

Establishment of a Novel Anti-Mouse CCR1 Monoclonal Antibody C1Mab-6 DOI
Tsunenori Ouchida,

Yu Isoda,

Takuro Nakamura

et al.

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, Journal Year: 2024, Volume and Issue: 43(2), P. 67 - 74

Published: March 21, 2024

C-C motif chemokine receptor 1 (CCR1/CD191) is a member of G-protein-coupled receptors and expressed on myeloid cells, such as neutrophils macrophages. Because the CCR1 signaling promotes tumor expansion in microenvironment (TME), modification TME an effective strategy for cancer therapy. Although attractive target solid tumors hematological malignancies, therapeutic agents have not been approved. Here, we established novel anti-mouse (mCCR1) monoclonal antibody (mAb), C

Language: Английский

Citations

5
Epitope Mapping of an Anti-Mouse CD39 Monoclonal Antibody Using PA Scanning and RIEDL Scanning DOI
Yuki Okada, Hiroyuki Suzuki, Tomohiro Tanaka

et al.

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, Journal Year: 2024, Volume and Issue: 43(2), P. 44 - 52

Published: March 20, 2024

A cell-surface ectonucleotidase CD39 mediates the conversion of extracellular adenosine triphosphate into immunosuppressive with another CD73. The elevated in tumor microenvironment attenuates antitumor immunity, which promotes cell immunologic escape and progression. Anti-CD39 monoclonal antibodies (mAbs), suppress enzymatic activity, can be applied to therapy. Therefore, an understanding relationship between inhibitory activity epitope mAbs is important. We previously established anti-mouse (anti-mCD39) mAb, C

Language: Английский

Citations

4
Establishment of a Highly-sensitive Anti-EphB2 Monoclonal Antibody Eb2Mab-3 for Flow Cytometry DOI Open Access

Rena Ubukata,

Hiroyuki Suzuki,

Miu Hirose

et al.

Published: June 11, 2024

EphB2 is a member of the Eph family tyrosine kinase receptors. binds to ephrin-B1, ephrin-B2, and ephrin-B3, which are critical regulators vascular nervous development through controlling cell migration axon guidance. overexpressed in tumors, including glioma, breast cancer, hepatocellular carcinoma, malignant mesothelioma, it functions as tumor promoter. Therefore, monoclonal antibodies (mAbs) against essential for diagnosis therapy EphB2-positive tumors. In this study, we developed novel mAbs human using Cell-Based Immunization Screening (CBIS) method. One established anti-EphB2 mAbs, Eb2Mab-3 (mouse IgG1, kappa), reacted with EphB2-overexpressed Chinese hamster ovary-K1 (CHO/EphB2) an endogenously EphB2-expressing cancer line (LS174T) by flow cytometry. Using cytometry, dissociation constant (KD) values CHO/EphB2 LS174T were determined 1.1 × 10−9 M 3.6 10−10 M, respectively. These results indicated that possesses high affinity detecting could apply therapy.

Language: Английский

Citations

1
Specificity of Aptamers U2 and Gol1 to EGFR-Positive Human Glioblastoma Cells in Vitro DOI
Fatima Dzarieva, Dzhirgala Shamadykova,

O. V. Sluchanko

et al.

Neuroscience and Behavioral Physiology, Journal Year: 2024, Volume and Issue: 54(6), P. 912 - 922

Published: July 1, 2024

Language: Английский

Citations

1
Establishment of a Novel Anti-mouse CCR1 Monoclonal Antibody C<sub>1</sub>Mab-6 DOI Open Access
Tsunenori Ouchida,

Yu Isoda,

Tomohiro Tanaka

et al.

Published: Dec. 27, 2023

C-C motif chemokine receptor 1 (CCR1/CD191) is a member of G-protein-coupled receptors, and expressed on myeloid cells, such as neutrophils macrophages. Because the CCR1 signaling promotes tumor expansion in microenvironment (TME), modification TME an effective strategy for cancer therapy. Although attractive target solid tumors hematological malignancies, anti-CCR1 therapeutic agents have not been approved. Here, we established novel anti-mouse (mCCR1) monoclonal antibody (mAb), C1Mab-6 (rat IgG2b, kappa), using Cell-Based Immunization Screening (CIBS) method. Flow cytometry Western blot analyses showed that recognizes mCCR1 specifically. The dissociation constant mCCR1-overexpressed Chinese hamster ovary-K1 was determined 3.9&times;10-9 M, indicating possesses high affinity to mCCR1. These results suggest could be useful tool targeting preclinical mouse models.

Language: Английский

Citations

3
Specificity of U2 and GOL1 aptamers to EGFR-positive human glioblastoma cells in vitro DOI
Fatima Dzarieva, Dzhirgala Shamadykova,

O. V. Sluchanko

et al.

Журнал высшей нервной деятельности им И П Павлова, Journal Year: 2024, Volume and Issue: 74(1), P. 85 - 99

Published: July 10, 2024

Language: Английский

Citations

0
Development of Highly Sensitive Anti-Mouse Epidermal Growth Factor Receptor 2 Monoclonal Antibodies for Flow Cytometry DOI Open Access
Tsunenori Ouchida, Hiroyuki Suzuki, Tomohiro Tanaka

et al.

Published: July 12, 2023

Overexpression of human epidermal growth factor receptor 2 (HER2) in breast cancer is an important target monoclonal antibody (mAb) therapy such as trastuzumab. Due to the development trastuzumab-deruxtecan, antibody-drug conjugate, targetable HER2-positive patients have been expanded. To evaluate developing modalities using anti-HER2 mAbs, reliable preclinical mouse models are required. Therefore, sensitive mAbs against HER2 (mHER2) should be established. This study developed mHER2 Cell-Based Immunization and Screening (CBIS) method. The established anti-mHER2 H2Mab-300 (rat IgG2b, kappa) H2Mab-304 IgG1, kappa), reacted with mHER2-overexpressed Chinese hamster ovary-K1 (CHO/mHER2) endogenously mHER2-expressed cell line, NMuMG (a mammary gland epithelial cell) by flow cytometry. Furthermore, these never recognized mHER2-knockout cells. kinetic analysis cytometry indicated that dissociation constant (KD) for CHO/mHER2 was 1.2 × 10−9 M 1.7 M, respectively. KD 4.9 10−10 9.0 These results could apply detection may useful obtain proof concept studies.

Language: Английский

Citations

1
Epitope Mapping of an Anti-Mouse CD39 Monoclonal Antibody using PA Scanning and RIEDL Scanning DOI Open Access
Hiroyuki Suzuki, Yuki Okada, Tomohiro Tanaka

et al.

Published: Dec. 6, 2023

A cell-surface ectonucleotidase CD39 mediates the conversion of extracellular ATP into immunosuppressive adenosine with another CD73. The elevated in tumor microenvironment (TME) attenuates antitumor immunity, which promotes cell immunologic escape and progression. Anti-CD39 monoclonal antibodies (mAbs), suppress enzymatic activity, can be applied to therapy. Therefore, an understanding relationship between inhibitory activity epitope mAbs is important. We previously established anti-mouse (mCD39) mAb, C39Mab-1 using Cell-Based Immunization Screening (CBIS) method. In this study, we determined critical flow cytometry. performed PA tag (12 amino acids)-substituted analysis (named scanning) RIEDL (5 determine By combination scanning scanning, identified conformational epitope, spanning three segments 275th 279th, 282nd 291st, 306th 323rd acids mCD39. These analyses would contribute identification membrane proteins.

Language: Английский

Citations

1